Prevention of mother-to-child transmission of HIV (PMTCT) programs have been incredibly successful across southern Africa. However, presentations at the second day of the Southern African HIV Clinicians Society Conference highlighted important gaps in pediatric testing and treatment.
PrEP could complement established HIV prevention strategies for pregnant and breastfeeding women as part of a comprehensive package to reduce HIV infections among women and transmission from mothers to infants in settings with high HIV incidence.
Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment. New WHO interim guidelines contain recommendations regarding preferred first-line regimens for adults, adolescents and children initiating ART, which now include DTG and RAL.
Children and adolescents have poorer HIV treatment outcomes than adults. We aimed to assess the effect of community-based support for caregivers of HIV-infected children and adolescents, who are key mediators to children engaging with care, on treatment outcomes.
Background: HIV self-testing (HIVST) can improve HIV-testing rates in ‘hard-to-reach’ populations, including men. We explored HIVST perceptions, delivery strategies, and post-test experiences among pregnant women and their male partners in Central Uganda.
Providing HIV self-testing kits to pregnant women to encourage HIV testing in their male partners is acceptable to men and women in Uganda, but women who are apprehensive about their partners’ reactions may need more support, according to findings from a qualitative study of participants in a ran
The Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative was a public-private partnership that expanded pediatric HIV services in nine sub-Saharan African countries from 2014-2016, providing treatment to more than 560,000 children living with HIV.
Background: The recent scale-up of prevention of mother-to-child transmission of HIV (PMTCT) services has rapidly accelerated antiretroviral therapy (ART) uptake among pregnant and postpartum women in sub-Saharan Africa.